MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

Key Takeaways

• Expansion in high-growth Life Science and Healthcare segments, supported by acquisitions and innovation, is positioning the company for stronger, more resilient future revenue and margin growth.
  
• Digital transformation and strategic divestments are enhancing operational efficiency, market share, and profitability through an increased focus on higher-margin businesses.
  
• Ongoing operational and external pressures across key segments threaten Merck KGaA's revenue growth, margins, and earnings stability, with heightened risks from competition and patent expiries.

Catalysts

Operates as a science and technology company in Germany.

• The robust and accelerating growth in the Life Science segment, particularly Process Solutions (with double-digit organic growth, strong order intake, and a sustained book-to-bill above 1), is being driven by increasing global investment and demand in biotechnology and advanced biologics manufacturing-this supports top-line revenue growth and higher operating leverage.
  
• The successful acquisition of SpringWorks and immediate contribution from high-growth, differentiated therapeutics such as Ogsiveo and Gomekli, alongside a solid pipeline (with launches such as pimicotinib expected in 2026), enhances Merck KGaA's future revenue streams and lays the groundwork for sustained margin expansion in healthcare.
  
• Structural tailwinds from the global aging population and rising chronic disease prevalence are set to drive continued demand for specialty pharmaceuticals and diagnostics across Merck KGaA's diversified portfolio, supporting long-term revenue growth and earnings resilience.
  
• Digitalization efforts-both in portfolio offerings (e.g., laboratory informatics, process automation, e-commerce channels in Life Science) and process improvements-position the company to capture incremental market share, drive productivity, and improve net margins as adoption accelerates in research and manufacturing settings.
  
• The divestment of Surface Solutions (a lower margin and less synergistic business) coupled with the expansion in higher-growth and higher-margin segments (notably Life Science consumables and Healthcare therapies) is shifting the mix toward structurally higher profitability, supporting the potential for medium-term improvements in net margins and EBITDA.

Merck KGaA Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Merck KGaA's revenue will grow by 4.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from 12.1% today to 14.4% in 3 years time.
• Analysts expect earnings to reach €3.4 billion (and earnings per share of €7.94) by about May 2029, up from €2.5 billion today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 21.2x on those 2029 earnings, down from 22.1x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 22.1x.
• Analysts expect the number of shares outstanding to decline by 0.2% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.26%, as per the Simply Wall St company report.

Risks

• The delayed recovery and persistent weakness in the DS&S (delivery systems and service) business within Semiconductor Solutions, along with pushed-out customer projects likely extending beyond 2025, point to ongoing headwinds for the Electronics segment; this is likely to negatively impact segment revenues and group net margins over the mid-term.
  
• Heightened foreign exchange headwinds, combined with the negative portfolio effects from the SpringWorks acquisition and Surface Solutions divestiture, are diluting reported earnings and compressing net profit margins, increasing vulnerability to currency fluctuations and shifting global trade policies.
  
• U.S. policy changes are causing ongoing caution among academic and government customers in Science & Lab Solutions, while the China market remains muted and overall pharma R&D spending remains closely monitored, raising the risk of protracted soft demand and stagnant sales in the lab segment-thereby pressuring group revenue growth.
  
• The Mavenclad patent expiry risk from 2026 onwards, as well as potential generic entry in the U.S. or staggered loss of exclusivity in Europe, poses a threat to the stability of the Healthcare segment's high profits and future earnings, with overdependence on a few blockbuster therapeutic areas (e.g., Mavenclad, Erbitux) amplifying medium-term revenue decline risk.
  
• Rising competitive pressures in new drug launches, as illustrated by Ogsiveo's market facing potential competition from AL102 (with possibly superior Phase III data), and the overall threat from biosimilars and generics, may erode pricing power and revenue streams in the long-term, further challenging net margins and overall earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of €143.33 for Merck KGaA based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €179.0, and the most bearish reporting a price target of just €121.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €23.6 billion, earnings will come to €3.4 billion, and it would be trading on a PE ratio of 21.2x, assuming you use a discount rate of 5.3%.
• Given the current share price of €128.6, the analyst price target of €143.33 is 10.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.